Inactive Instrument

Isofol Medical AB (publ) Share Price Nasdaq Stockholm

Equities

SE0009581051

Pharmaceuticals

Financials

Sales 2021 22.41M 2.07M 165M Sales 2022 12.8M 1.18M 94.3M Capitalization 120M 11.05M 881M
Net income 2021 -200M -18.49M -1.47B Net income 2022 -160M -14.79M -1.18B EV / Sales 2021 49.7 x
Net cash position 2021 378M 34.93M 2.78B Net cash position 2022 187M 17.26M 1.38B EV / Sales 2022 -5.24 x
P/E ratio 2021
-5.8 x
P/E ratio 2022
-0.75 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 62.57%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 72 01-08
Director of Finance/CFO 68 01-09
Chief Tech/Sci/R&D Officer 59 31/01/19
Members of the board TitleAgeSince
Chairman 83 -
Director/Board Member 76 01-03
Director/Board Member 74 31/12/17
More insiders
Isofol Medical AB (publ) is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The Company cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Company’s main shareholders are Biofol AB and Yield Life Science AB.
Calendar
More about the company